COMPUTED DESCRIPTORS
| Molecular Weight | 5136 g/mol |
|---|---|
| XLogP3 | -23.3 |
| Hydrogen Bond Donor Count | 83 |
| Hydrogen Bond Acceptor Count | 76 |
| Rotatable Bond Count | 187 |
| Exact Mass | 5134.7233503 g/mol |
| Monoisotopic Mass | 5132.7166406 g/mol |
| Topological Polar Surface Area | 2360 Ų |
| Heavy Atom Count | 361 |
| Formal Charge | 0 |
| Complexity | 12800 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 44 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently-Bonded Unit Count | 1 |
| Compound Is Canonicalized | Yes |
PRODUCT INTRODUCTION
description
Tesamorelin is a synthetic growth hormone releasing hormone analogue used in the treatment of visceral adiposity in human immunodeficiency virus (HIV) infected patients with lipodystrophy. Tesamorelin is given subcutaneously and has major effects on glucose and lipid metabolism, but has not been linked to serum aminotransferase elevations during therapy or to instances of clinically apparent acute liver injury.